KDR/PDGFRb/FLT kinase inhibitors (Origenis)

N/A

Report date: 2025/03/20 20:00:06

NME

Base Information

Drug NameKDR/PDGFRb/FLT kinase inhibitors (Origenis)

Drug Alias Namemulti-target kinase inhibitors (Origenis)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPlatelet-derived growth factor receptor beta inhibitorsFms-related tyrosine kinase 3 ligand inhibitorsVascular endothelial growth factor receptor 2 antagonists

TargetsFms-related tyrosine kinase 3 ligandVascular endothelial growth factor receptor 2Platelet-derived growth factor receptor beta

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesOrigenis GmbH

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesOrigenis GmbH

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A